miRNA Regulatory Pathway in Neurodegeneration

Overview

MicroRNAs (miRNAs) are short non-coding RNAs that tune post-transcriptional gene expression by guiding Argonaute-containing RNA-induced silencing complexes (RISCs) to target transcripts.^{1'MicroRNAs: genomics, biogenesis, mechanism, and function'2004 · Cell · DOI 10.1016/S0092-8674(04Open reference2Regulation of microRNA biogenesis and its crosstalk with other cellular pathways2019 · Nature Reviews Genetics · DOI 10.1038/s41576-019-0152-9Open reference} In the nervous system, this buffering function is central to synaptic plasticity, immune homeostasis, stress adaptation, and cell-survival programs.^{2Regulation of microRNA biogenesis and its crosstalk with other cellular pathways2019 · Nature Reviews Genetics · DOI 10.1038/s41576-019-0152-9Open reference3Regulation of microRNA biogenesis2014 · Nature Reviews Molecular Cell Biology · DOI 10.1038/nrm3838Open reference} Neurodegenerative diseases show convergent failure of this layer of control: miRNA biogenesis weakens, cell-type-specific miRNA programs drift, and compensatory immune miRNAs become chronically activated.^{3Regulation of microRNA biogenesis2014 · Nature Reviews Molecular Cell Biology · DOI 10.1038/nrm3838Open reference4MicroRNA and neurodegenerative disease2023 · Cellular and Molecular Neurobiology · PMID 35671534Open reference}

In practical terms, the miRNA pathway links upstream stressors (protein aggregation, mitochondrial dysfunction, oxidative stress, endolysosomal stress) to downstream outcomes (aberrant APP processing, tau phosphorylation pressure, alpha-synuclein accumulation, maladaptive neuroinflammation, and circuit failure).^{4MicroRNA and neurodegenerative disease2023 · Cellular and Molecular Neurobiology · PMID 35671534Open reference5Non-coding RNAs in neurodegeneration2021 · Trends in Neurosciences · PMID 33961952Open reference6MicroRNA and neuroinflammation2022 · Journal of Neuroinflammation · PMID 35164756Open reference} Because each miRNA can regulate many targets, modest changes in abundance can drive broad network-level shifts, making miRNAs attractive biomarkers and potential therapeutic leverage points.^{7Circulating miRNAs as biomarkers2023 · Molecular Neurobiology · PMID 37402568Open reference2Regulation of microRNA biogenesis and its crosstalk with other cellular pathways2019 · Nature Reviews Genetics · DOI 10.1038/s41576-019-0152-9Open reference}0

This page synthesizes mechanistic steps from biogenesis to disease phenotypes, with a focus on Alzheimer’s disease (AD) and Parkinson’s disease (PD), and translational implications for related 4R-tau disorders such as Progressive Supranuclear Palsy and Corticobasal Degeneration.

Core Biogenesis And Effector Logic

flowchart TD
    A["Pol II/III transcription"]  -->  B["pri-miRNA hairpin"]
    B  -->  C["Drosha-DGCR8 microprocessor"]
    C  -->  D["pre-miRNA export via XPO5-RAN"]
    D  -->  E["Dicer cleavage in cytoplasm"]
    E  -->  F["miRNA duplex"]
    F  -->  G["AGO loading and strand selection"]
    G  -->  H["RISC target recognition at 3' UTR"]
    H  -->  I["Translational repression / mRNA decay"]
    I  -->  J["Network effects in neurons and glia"]

    J  -->  K["APP/BACE1 and amyloid pressure"]
    J  -->  L["Tau kinase-phosphatase balance"]
    J  -->  M["Alpha-synuclein proteostasis"]
    J  -->  N["Microglial inflammatory setpoint"]
    J  -->  O["Mitochondrial resilience / ROS handling"]

    K  -->  P["Synaptic dysfunction"]
    L  -->  P
    M  -->  P
    N  -->  Q["Neuroinflammation"]
    O  -->  R["Bioenergetic failure"]
    P  -->  S["Neurodegeneration"]
    Q  -->  S
    R  -->  S

Biogenesis Nodes With Disease Relevance

1. Drosha-DGCR8 microprocessor: Nuclear cleavage of pri-miRNA into pre-miRNA is a high-sensitivity failure point under chronic stress.^{2Regulation of microRNA biogenesis and its crosstalk with other cellular pathways2019 · Nature Reviews Genetics · DOI 10.1038/s41576-019-0152-9Open reference}1^{2Regulation of microRNA biogenesis and its crosstalk with other cellular pathways2019 · Nature Reviews Genetics · DOI 10.1038/s41576-019-0152-9Open reference}2

2. Export machinery (XPO5/RAN): Export bottlenecks alter mature-miRNA supply and may preferentially impact stress-responsive families.^{2Regulation of microRNA biogenesis and its crosstalk with other cellular pathways2019 · Nature Reviews Genetics · DOI 10.1038/s41576-019-0152-9Open reference}3

3. Dicer axis: Reduced Dicer activity has been associated with age-related vulnerability and degeneration-relevant transcriptomic noise.^{2Regulation of microRNA biogenesis and its crosstalk with other cellular pathways2019 · Nature Reviews Genetics · DOI 10.1038/s41576-019-0152-9Open reference}4^{2Regulation of microRNA biogenesis and its crosstalk with other cellular pathways2019 · Nature Reviews Genetics · DOI 10.1038/s41576-019-0152-9Open reference}5

4. AGO/RISC occupancy: Targeting efficacy depends on AGO availability, seed matching, and local RNA-binding protein context.^{2Regulation of microRNA biogenesis and its crosstalk with other cellular pathways2019 · Nature Reviews Genetics · DOI 10.1038/s41576-019-0152-9Open reference}6^{2Regulation of microRNA biogenesis and its crosstalk with other cellular pathways2019 · Nature Reviews Genetics · DOI 10.1038/s41576-019-0152-9Open reference}7

5. Decay/turnover: Mature miRNA half-life and target-directed miRNA degradation shape time-dependent responses in neurons and glia.^{2Regulation of microRNA biogenesis and its crosstalk with other cellular pathways2019 · Nature Reviews Genetics · DOI 10.1038/s41576-019-0152-9Open reference}8

Alzheimer’s Disease: Key miRNA Programs

AD-relevant miRNA changes are best interpreted as network perturbations rather than single-marker events. The strongest recurring axis involves BACE1 and APP processing pressure, with secondary effects on neuroinflammation, synaptic maintenance, and tau-modifying signaling.

miR-29 Family (miR-29a/b)

Reduced miR-29 signaling has repeatedly been linked to increased BACE1 expression and elevated amyloidogenic processing pressure.^{2Regulation of microRNA biogenesis and its crosstalk with other cellular pathways2019 · Nature Reviews Genetics · DOI 10.1038/s41576-019-0152-9Open reference}9^{2Regulation of microRNA biogenesis and its crosstalk with other cellular pathways2019 · Nature Reviews Genetics · DOI 10.1038/s41576-019-0152-9Open reference}0 This relationship provides one mechanistic route by which apparently modest miRNA changes can influence long-horizon amyloid load. In advanced disease, inflammatory and metabolic stress can further destabilize this axis, compounding feed-forward pathology.^{2Regulation of microRNA biogenesis and its crosstalk with other cellular pathways2019 · Nature Reviews Genetics · DOI 10.1038/s41576-019-0152-9Open reference}1^{2Regulation of microRNA biogenesis and its crosstalk with other cellular pathways2019 · Nature Reviews Genetics · DOI 10.1038/s41576-019-0152-9Open reference}2

miR-107

Early reduction of miR-107 in AD cortex has been associated with increased BACE1 and faster progression signatures, consistent with a role in prodromal molecular drift.^{2Regulation of microRNA biogenesis and its crosstalk with other cellular pathways2019 · Nature Reviews Genetics · DOI 10.1038/s41576-019-0152-9Open reference}3^{2Regulation of microRNA biogenesis and its crosstalk with other cellular pathways2019 · Nature Reviews Genetics · DOI 10.1038/s41576-019-0152-9Open reference}4 Translationally, this makes miR-107 a candidate bridge between biomarker detection and mechanism-based stratification.

miR-146a And miR-155 (Immune-Inflammatory Setpoints)

miR-146a is generally interpreted as an inflammation-feedback regulator downstream of NF-kappaB pathways, while miR-155 often tracks pro-inflammatory glial activation states.^{2Regulation of microRNA biogenesis and its crosstalk with other cellular pathways2019 · Nature Reviews Genetics · DOI 10.1038/s41576-019-0152-9Open reference}5^{2Regulation of microRNA biogenesis and its crosstalk with other cellular pathways2019 · Nature Reviews Genetics · DOI 10.1038/s41576-019-0152-9Open reference}6^{2Regulation of microRNA biogenesis and its crosstalk with other cellular pathways2019 · Nature Reviews Genetics · DOI 10.1038/s41576-019-0152-9Open reference}7 In AD, chronic induction of these immune miRNAs likely reflects sustained innate-immune stress rather than successful resolution, especially when combined with persistent amyloid/tau signals.^{2Regulation of microRNA biogenesis and its crosstalk with other cellular pathways2019 · Nature Reviews Genetics · DOI 10.1038/s41576-019-0152-9Open reference}8^{2Regulation of microRNA biogenesis and its crosstalk with other cellular pathways2019 · Nature Reviews Genetics · DOI 10.1038/s41576-019-0152-9Open reference}9

miR-9

miR-9 contributes to neuronal identity programs and synaptic regulation; dysregulation in AD is linked to loss of adaptive plasticity and impaired transcriptional homeostasis.^{3Regulation of microRNA biogenesis2014 · Nature Reviews Molecular Cell Biology · DOI 10.1038/nrm3838Open reference}0^{3Regulation of microRNA biogenesis2014 · Nature Reviews Molecular Cell Biology · DOI 10.1038/nrm3838Open reference}1 Because miR-9 also interfaces with neurodevelopmental and adult plasticity modules, its disturbance may amplify selective regional vulnerability.

Parkinson’s Disease: Key miRNA Programs

PD miRNA biology converges on alpha-synuclein homeostasis, mitochondrial stress handling, and inflammatory context. Disturbance of miRNAs that normally suppress SNCA translation is a central recurring motif.

miR-7

miR-7 is among the best-described suppressors of alpha-synuclein translation and is also tied to oxidative-stress resilience pathways.^{3Regulation of microRNA biogenesis2014 · Nature Reviews Molecular Cell Biology · DOI 10.1038/nrm3838Open reference}2^{3Regulation of microRNA biogenesis2014 · Nature Reviews Molecular Cell Biology · DOI 10.1038/nrm3838Open reference}3 Lower effective miR-7 activity can therefore increase SNCA burden while weakening stress defenses, a dual hit relevant to dopaminergic neuronal vulnerability.

miR-153

miR-153 cooperates with miR-7 in restraining alpha-synuclein expression; loss of this buffering pair can accelerate proteostatic overload.^{3Regulation of microRNA biogenesis2014 · Nature Reviews Molecular Cell Biology · DOI 10.1038/nrm3838Open reference}4^{3Regulation of microRNA biogenesis2014 · Nature Reviews Molecular Cell Biology · DOI 10.1038/nrm3838Open reference}5 This is a prime example of combinatorial miRNA control where parallel weak perturbations can produce strong phenotype shifts.

miR-124

miR-124 has broad neuron-glia regulatory roles and is frequently linked to anti-inflammatory and pro-neuronal maintenance programs in PD-relevant models.^{3Regulation of microRNA biogenesis2014 · Nature Reviews Molecular Cell Biology · DOI 10.1038/nrm3838Open reference}6^{3Regulation of microRNA biogenesis2014 · Nature Reviews Molecular Cell Biology · DOI 10.1038/nrm3838Open reference}7 In disease contexts, failure to sustain miR-124 signaling can bias microglia toward persistent inflammatory phenotypes and weaken neuronal repair tone.

miR-184

miR-184 is less mature than miR-7/miR-153 evidence-wise but has been reported in PD-relevant regulatory circuits involving survival signaling and stress adaptation.^{3Regulation of microRNA biogenesis2014 · Nature Reviews Molecular Cell Biology · DOI 10.1038/nrm3838Open reference}8^{3Regulation of microRNA biogenesis2014 · Nature Reviews Molecular Cell Biology · DOI 10.1038/nrm3838Open reference}9 At present, it is best treated as a candidate network modulator requiring better replication across cohorts and biospecimen types.

Cross-Disease Mechanistic Convergence

1. Proteostasis Coupling

miRNA dysregulation influences expression of chaperones, ubiquitin-proteasome components, autophagy regulators, and aggregation-prone proteins.^{3Regulation of microRNA biogenesis2014 · Nature Reviews Molecular Cell Biology · DOI 10.1038/nrm3838Open reference}0^{3Regulation of microRNA biogenesis2014 · Nature Reviews Molecular Cell Biology · DOI 10.1038/nrm3838Open reference}1 In AD this accentuates APP/tau pressure; in PD it amplifies alpha-synuclein load and lysosomal stress.

2. Neuroinflammatory Setpoint Drift

Persistent perturbation of inflammation-linked miRNAs (notably miR-146a/miR-155/miR-124) shifts glial states toward chronic injury-associated phenotypes, reducing the probability of true inflammatory resolution.^{3Regulation of microRNA biogenesis2014 · Nature Reviews Molecular Cell Biology · DOI 10.1038/nrm3838Open reference}2^{3Regulation of microRNA biogenesis2014 · Nature Reviews Molecular Cell Biology · DOI 10.1038/nrm3838Open reference}3^{3Regulation of microRNA biogenesis2014 · Nature Reviews Molecular Cell Biology · DOI 10.1038/nrm3838Open reference}4

3. Bioenergetic And Mitochondrial Vulnerability

miRNA-controlled programs influence mitochondrial biogenesis, ROS handling, and metabolic flexibility, creating disease-agnostic vulnerability when stress is sustained.^{3Regulation of microRNA biogenesis2014 · Nature Reviews Molecular Cell Biology · DOI 10.1038/nrm3838Open reference}5^{3Regulation of microRNA biogenesis2014 · Nature Reviews Molecular Cell Biology · DOI 10.1038/nrm3838Open reference}6^{3Regulation of microRNA biogenesis2014 · Nature Reviews Molecular Cell Biology · DOI 10.1038/nrm3838Open reference}7

4. Network-Level Nonlinearity

Because one miRNA can regulate many targets and one transcript can be regulated by many miRNAs, small abundance changes can produce nonlinear effects on pathway states.^{3Regulation of microRNA biogenesis2014 · Nature Reviews Molecular Cell Biology · DOI 10.1038/nrm3838Open reference}8^{3Regulation of microRNA biogenesis2014 · Nature Reviews Molecular Cell Biology · DOI 10.1038/nrm3838Open reference}9^{4MicroRNA and neurodegenerative disease2023 · Cellular and Molecular Neurobiology · PMID 35671534Open reference}0 This helps explain heterogeneous trajectories and stage-specific reversals in observational datasets.

CBS/PSP-Specific Relevance

Direct CBS/PSP miRNA interventional data remain limited, but mechanistic transfer from AD/PD and primary tauopathy literature suggests several high-priority hypotheses:

1. Tau kinase-phosphatase control: miRNA programs that influence GSK3beta/ERK/CDK5/PP2A balance may affect 4R-tau phosphorylation burden in vulnerable cortico-basal and brainstem circuits.^{4MicroRNA and neurodegenerative disease2023 · Cellular and Molecular Neurobiology · PMID 35671534Open reference}1^{4MicroRNA and neurodegenerative disease2023 · Cellular and Molecular Neurobiology · PMID 35671534Open reference}2

2. Glial inflammatory tone: chronic microglial setpoint drift (miR-146a/miR-155 patterns) may accelerate white-matter and corticobasal network dysfunction.^{4MicroRNA and neurodegenerative disease2023 · Cellular and Molecular Neurobiology · PMID 35671534Open reference}3^{4MicroRNA and neurodegenerative disease2023 · Cellular and Molecular Neurobiology · PMID 35671534Open reference}4

3. Biomarker staging: CSF/plasma/exosomal miRNA panels could support disease-staging and treatment-response monitoring when combined with clinical phenotyping.^{4MicroRNA and neurodegenerative disease2023 · Cellular and Molecular Neurobiology · PMID 35671534Open reference}5^{4MicroRNA and neurodegenerative disease2023 · Cellular and Molecular Neurobiology · PMID 35671534Open reference}6

These are actionable as trial-stratification and longitudinal biomarker priorities, even before definitive standalone therapeutic efficacy is proven in CBS/PSP cohorts.

Therapeutic Strategies And Delivery Constraints

miRNA Inhibition (Antagomirs/LNAs)

Inhibition is best suited for pathogenic gain-of-function miRNA states (for example persistent pro-inflammatory signatures). Chemically stabilized antisense approaches can be potent but require careful off-target and exposure control.^{4MicroRNA and neurodegenerative disease2023 · Cellular and Molecular Neurobiology · PMID 35671534Open reference}7^{4MicroRNA and neurodegenerative disease2023 · Cellular and Molecular Neurobiology · PMID 35671534Open reference}8

miRNA Replacement (Mimics)

Replacement aims to restore protective loss-of-function states (for example miR-29/miR-107 or miR-7/miR-153 programs). Major barriers remain tissue-selective delivery, endosomal escape, and sustained target engagement in brain-relevant compartments.^{4MicroRNA and neurodegenerative disease2023 · Cellular and Molecular Neurobiology · PMID 35671534Open reference}9^{4MicroRNA and neurodegenerative disease2023 · Cellular and Molecular Neurobiology · PMID 35671534Open reference}0

Vector And Vesicle Platforms

AAV, lipid nanoparticles, and engineered extracellular vesicles are the principal delivery platforms under active investigation.^{4MicroRNA and neurodegenerative disease2023 · Cellular and Molecular Neurobiology · PMID 35671534Open reference}1^{4MicroRNA and neurodegenerative disease2023 · Cellular and Molecular Neurobiology · PMID 35671534Open reference}2 Each has trade-offs across payload size, redosing feasibility, immunogenicity, and manufacturing complexity.

Safety Architecture

Given the broad target-space of each miRNA, development programs need explicit safety architecture:

1. Prioritized on-target network maps (intended vs collateral transcript sets)

2. Stage-aware dose-escalation with transcriptomic pharmacodynamics

3. Orthogonal biomarkers (fluid + imaging + digital phenotyping)

4. Prespecified stopping rules for neuroinflammatory worsening or cognitive/motor acceleration

Translational Implementation Framework

For near-term translational work in AD/PD/CBS/PSP-enriched cohorts:

1. Discovery layer: harmonized plasma/CSF/exosome profiling with strict pre-analytic controls.^{4MicroRNA and neurodegenerative disease2023 · Cellular and Molecular Neurobiology · PMID 35671534Open reference}3^{4MicroRNA and neurodegenerative disease2023 · Cellular and Molecular Neurobiology · PMID 35671534Open reference}4

2. Mechanistic layer: integrated target-network and pathway-level analyses anchored to disease biology.^{4MicroRNA and neurodegenerative disease2023 · Cellular and Molecular Neurobiology · PMID 35671534Open reference}5^{4MicroRNA and neurodegenerative disease2023 · Cellular and Molecular Neurobiology · PMID 35671534Open reference}6

3. Interventional layer: adaptive, biomarker-guided early-phase studies with longitudinal molecular readouts.^{4MicroRNA and neurodegenerative disease2023 · Cellular and Molecular Neurobiology · PMID 35671534Open reference}7^{4MicroRNA and neurodegenerative disease2023 · Cellular and Molecular Neurobiology · PMID 35671534Open reference}8

4. Replication layer: multi-site validation emphasizing assay reproducibility and clinically meaningful endpoints.^{4MicroRNA and neurodegenerative disease2023 · Cellular and Molecular Neurobiology · PMID 35671534Open reference}9^{5Non-coding RNAs in neurodegeneration2021 · Trends in Neurosciences · PMID 33961952Open reference}0

Cell-Type And Compartment Interpretation

miRNA signals should be interpreted in explicit biological compartments because directionality and effect size can diverge between tissue, CSF, plasma, and extracellular vesicle (EV) fractions.

1. Neuron-enriched programs: miR-7 and miR-153 are most informative when interpreted against alpha-synuclein burden and dopaminergic vulnerability context, rather than as standalone classifiers.^{5Non-coding RNAs in neurodegeneration2021 · Trends in Neurosciences · PMID 33961952Open reference}1^{5Non-coding RNAs in neurodegeneration2021 · Trends in Neurosciences · PMID 33961952Open reference}2^{5Non-coding RNAs in neurodegeneration2021 · Trends in Neurosciences · PMID 33961952Open reference}3

2. Immune-glial programs: miR-146a and miR-155 shifts are often strongest in inflammation-biased compartments and may represent dynamic glial-state changes rather than fixed disease identity markers.^{5Non-coding RNAs in neurodegeneration2021 · Trends in Neurosciences · PMID 33961952Open reference}4^{5Non-coding RNAs in neurodegeneration2021 · Trends in Neurosciences · PMID 33961952Open reference}5^{5Non-coding RNAs in neurodegeneration2021 · Trends in Neurosciences · PMID 33961952Open reference}6

3. Vesicle-enriched programs: EV-associated miRNAs can better reflect CNS-relevant biology than bulk plasma in some cohorts, but pre-analytic handling and isolation method strongly affect reproducibility.^{5Non-coding RNAs in neurodegeneration2021 · Trends in Neurosciences · PMID 33961952Open reference}7^{5Non-coding RNAs in neurodegeneration2021 · Trends in Neurosciences · PMID 33961952Open reference}8^{5Non-coding RNAs in neurodegeneration2021 · Trends in Neurosciences · PMID 33961952Open reference}9

4. Stage dependence: prodromal, early symptomatic, and advanced disease windows can show different miRNA directionality for the same transcript, requiring longitudinal rather than cross-sectional interpretation.^{6MicroRNA and neuroinflammation2022 · Journal of Neuroinflammation · PMID 35164756Open reference}0^{6MicroRNA and neuroinflammation2022 · Journal of Neuroinflammation · PMID 35164756Open reference}1^{6MicroRNA and neuroinflammation2022 · Journal of Neuroinflammation · PMID 35164756Open reference}2

Operationally, this argues for trial protocols that predefine compartment hierarchy (for example CSF EVs primary, plasma secondary), lock extraction/QC pipelines before enrollment, and pair molecular endpoints with phenotypes (motor progression, cognition, imaging, autonomic burden).

Clinical Translation Status And Trial Design

Current evidence supports two near-term paths: (1) miRNA biomarkers for enrichment/monitoring and (2) early mechanism-targeted therapeutic pilots.

Biomarker-Enrichment Path

• Use multimarker panels instead of single miRNAs to reduce noise and improve transportability across sites.^{6MicroRNA and neuroinflammation2022 · Journal of Neuroinflammation · PMID 35164756Open reference}3^{6MicroRNA and neuroinflammation2022 · Journal of Neuroinflammation · PMID 35164756Open reference}4

• Anchor panel interpretation to mechanistic modules (amyloid processing, alpha-synuclein control, inflammatory tone) rather than diagnosis labels alone.^{6MicroRNA and neuroinflammation2022 · Journal of Neuroinflammation · PMID 35164756Open reference}5^{6MicroRNA and neuroinflammation2022 · Journal of Neuroinflammation · PMID 35164756Open reference}6

• Embed longitudinal sampling at predefined disease milestones and treatment changes.^{6MicroRNA and neuroinflammation2022 · Journal of Neuroinflammation · PMID 35164756Open reference}7^{6MicroRNA and neuroinflammation2022 · Journal of Neuroinflammation · PMID 35164756Open reference}8

Therapeutic Pilot Path

• Prioritize replacement strategies for consistent loss-of-function patterns (for example miR-29/miR-107 and miR-7/miR-153 axes) and inhibition strategies for persistent inflammatory overactivation states.^{6MicroRNA and neuroinflammation2022 · Journal of Neuroinflammation · PMID 35164756Open reference}9^{7Circulating miRNAs as biomarkers2023 · Molecular Neurobiology · PMID 37402568Open reference}0^{7Circulating miRNAs as biomarkers2023 · Molecular Neurobiology · PMID 37402568Open reference}1^{7Circulating miRNAs as biomarkers2023 · Molecular Neurobiology · PMID 37402568Open reference}2^{7Circulating miRNAs as biomarkers2023 · Molecular Neurobiology · PMID 37402568Open reference}3

• Require pharmacodynamic readouts that confirm target-network engagement before efficacy claims (transcript shifts, pathway markers, imaging-aligned endpoints).^{7Circulating miRNAs as biomarkers2023 · Molecular Neurobiology · PMID 37402568Open reference}4^{7Circulating miRNAs as biomarkers2023 · Molecular Neurobiology · PMID 37402568Open reference}5^{7Circulating miRNAs as biomarkers2023 · Molecular Neurobiology · PMID 37402568Open reference}6

• Include safety sentinels for immune activation, off-target network disruption, and CNS delivery-related adverse events, with prespecified pausing/stopping triggers.^{7Circulating miRNAs as biomarkers2023 · Molecular Neurobiology · PMID 37402568Open reference}7^{7Circulating miRNAs as biomarkers2023 · Molecular Neurobiology · PMID 37402568Open reference}8

Decision-Ready Framework For AD/PD/CBS/PSP Programs

1. Mechanistic eligibility: enrollment requires baseline dysregulation in the target miRNA module.

2. Compartment lock: one primary assay compartment is frozen pre-trial to avoid post hoc signal mining.

3. Exposure-response checkpoint: early interim confirms molecular engagement before expansion.

4. Clinical integration: molecular endpoints are interpreted jointly with standardized motor/cognitive/autonomic outcomes.

5. Replication gate: progression to larger studies requires independent cohort reproduction with the same assay protocol.

Evidence Rubric Snapshot

Total: 47/80

See Also

• RNA Metabolism Dysregulation Pathway

• Epigenetic Dysregulation Pathway

• Neuroinflammation Pathway

• Alpha-Synuclein Aggregation Pathway

• Tau Pathology Pathway

• Alzheimer’s Disease

• Parkinson’s Disease

• Progressive Supranuclear Palsy

• Corticobasal Degeneration

• MicroRNA (miRNA) Biomarkers in Neurodegenerative Disease

Recent Research Updates (2024-2026)

• Y et al. 2024: Mitochondrial dysfunction: mechanisms and advances in therapy.

• H et al. 2025: Update in the molecular mechanism and biomarkers of diabetic retinopat

• KM et al. 2025: Exploring the bioactivity of MicroRNAs Originated from Plant-derived E

• Q et al. 2026: MicroRNA-155 in neurodegeneration.

• P et al. 2024: Apolipoprotein E dysfunction in Alzheimer’s disease: a study on miRNA